['hyperlipidemia']
['etc-1002', 'atorvastatin', 'placebo']

        Inclusion Criteria:

          -  Taking daily stable statin doses for at least 4 weeks prior to screening visit.

          -  LDL-C between 100-220 mg/dL for patients taking daily high-intensity statin (for 4
             weeks prior to switching to sponsor -provided atorvastatin 80 mg/day and stopping all
             other lipid-regulating drugs and supplements) at the screening visit; or,

          -  LDL-C between 115-220 mg/dL for patients taking moderate- or low-intensity statin (for
             4 weeks prior to switching to sponsor -provided atorvastatin 80 mg/day and stopping
             all other lipid-regulating drugs and supplements) at the screening visit.

          -  Must be willing to discontinue other lipid-regulating therapies during the study

        Exclusion Criteria:

          -  History of acute significant cardiovascular disease.

          -  Current clinically significant cardiovascular disease.

          -  History of inability to tolerate any statin at any dose due to muscle-related pain or
             weakness.
      